Harbor is now

Weight Loss Pills vs Weight Loss Injections, How They Differ

Both routes now include GLP-1 medicines. One is a shot once a week, the other a tablet every day, sometimes on an empty stomach. Here is how the labels compare, and where a clinician fits.

Clinically reviewed
Medically reviewed by Harbor Health TeamMedical Content Team8 min read

At a glance

FDA labels & NIDDK, separate brand trials
One dose a week

Weight loss shots

Weekly GLP-1 injections

  • TakenOnce a week
  • Food rulesNone
  • NeedleYes
  • CompoundedNot FDA approved

Weight loss pills

Daily tablets & capsules

7Key numberto 21 (Doses a week)

  • TakenEvery day
  • Food rulesVary by pill
  • NeedleNone
  • CompoundedNot offered

The verdict: Weekly injections fit adults who want one dose a week with no food rules, and Harbor's semaglutide and tirzepatide programs, which are compounded and not FDA approved, pair that routine with physician review, one flat price and registered-dietitian aftercare. Every trial figure here is from a brand drug, and the pills named here are FDA approved but taken every day.

Weight loss pills vs injections verdict

The weight loss pills vs injections choice comes down to routine and access, because both groups now include GLP-1 medicines. A weekly injection is one dose on the same day each week, at any time of day, with or without meals. A pill is taken every day, and the Wegovy pill has to be taken on an empty stomach, followed by a 30-minute wait before food.

Harbor's two weight-loss programs use the weekly injection. A board-certified physician reviews your health history before anything ships, medication, clinician care and check-ins sit in one flat price with no insurance required, and the program is designed to end with a clinician-guided taper and registered-dietitian aftercare. Its semaglutide and tirzepatide are compounded and are not FDA approved.

Pills have clear strengths of their own. They need no needle, every pill named in this post is FDA approved, and two of them are GLP-1 tablets with their own trial records. Neither route is a shortcut. Here is how the labels line up.

Pills vs injections side by side

Weight loss injections and pills overlap more than they used to, because semaglutide now comes both ways. That makes the Wegovy pill vs injection the cleanest test case: one drug, one label, two forms.

How each one is taken

Wegovy injection is given once weekly, on the same day each week, at any time of day, with or without meals, under the skin of the abdomen, thigh or upper arm (Wegovy label). Zepbound follows the same weekly pattern. The compounded semaglutide and tirzepatide in these programs, which are not FDA approved, are also once-weekly injections you give yourself at home, drawn from a vial with a U-100 insulin syringe.

Oral semaglutide asks more of your morning. Wegovy tablets are taken once daily on an empty stomach with up to 4 ounces of water, swallowed whole, and followed by a wait of at least 30 minutes before eating, drinking or taking other oral medicines. Foundayo is taken once daily, with or without food (Foundayo label). Among the older pills, NIDDK lists orlistat at three times a day, Qsymia at once a day and Contrave at one to two times a day.

One habit a week, or one every morning. That is the practical difference.

What the trials show

Each figure below comes from a brand drug's own label trial. The trials were separate, with different lengths and populations, so do not read the numbers as a ranking of one drug over the next.

  • STEP 1, Wegovy injection 2.4 mg: mean weight change of −14.9% at 68 weeks, against −2.4% on placebo, in 1,961 adults.
  • OASIS 4, Wegovy tablets 25 mg: −13.6% at 64 weeks, against −2.4% on placebo, in 307 adults.
  • ATTAIN-1, Foundayo 17.2 mg: −11.1% at 72 weeks, against −2.1% on placebo, in 3,127 adults.
  • SURMOUNT-1, Zepbound 15 mg: −20.9% at 72 weeks, against −3.1% on placebo, in 2,539 adults.

On those labels the two forms of semaglutide land close together, and the largest figure belongs to brand tirzepatide by injection (Zepbound label). Compounded semaglutide and tirzepatide, which are not FDA approved, were not the drugs tested in any of these trials. A trial average is also not a personal forecast.

For the wider group, NIDDK says adults who take a prescription weight management medication as part of a lifestyle program lose, on average, 3% to 12% more of their starting weight after a year than people in a lifestyle program alone.

FDA approval & who qualifies

For adults, form does not change who the labels are written for. Wegovy injection, Wegovy tablets, Zepbound and Foundayo are each indicated, with a reduced-calorie diet and increased physical activity, to reduce excess body weight and maintain weight reduction long term in adults with obesity, or in adults with overweight plus one or more conditions tied to weight.

Not every oral semaglutide is a weight loss pill. Rybelsus and Ozempic tablets are oral semaglutide too, and their label covers adults with type 2 diabetes. Weight management is not on it.

Compounded semaglutide and tirzepatide sit outside that approval system. Compounded drugs are not FDA approved, which means FDA does not verify their safety, effectiveness or quality before they are marketed (FDA). A licensed clinician has to prescribe them, and decides whether they are appropriate for you.

Cost & access

What a brand pill or pen costs you depends on your plan. NIDDK notes that some, but not all, insurance plans cover medications that treat overweight and obesity, so the first step on the brand route is a call to your insurer.

The cash route is simpler to read. Through Harbor, the semaglutide program starts at $89 a month and the tirzepatide program at $119 a month (compounded, not FDA approved). Each is one flat price that includes medication, clinician care and check-ins, with no insurance required and HSA or FSA cards accepted. The program page describes the price as "Flat as your dose goes up."

Members notice that part. In an August 23, 2026 Trustpilot review, member Kendra Freeman wrote, "Needing to up your dose great no problem costs stay the same." When you compare any two prices, check what each one covers: the drug alone, or the drug plus the clinician.

From the Wegovy, Zepbound and Foundayo prescribing information, NIDDK and the program pages, checked November 16, 2026. Trial figures are from brand drugs in separate trials, not a head-to-head comparison. Compounded semaglutide and tirzepatide are not FDA approved.
AttributeWeight loss shotsWeight loss pills
What is in the groupWegovy (semaglutide) and Zepbound (tirzepatide), plus compounded semaglutide and tirzepatide, which are not FDA approvedWegovy tablets, Foundayo, Qsymia, Contrave and orlistat
How oftenOnce a week Fewer dosesEvery day, from once to three times a day
Food & timing rulesAny time of day, with or without meals No food rulesWegovy tablets: empty stomach, then a 30-minute wait. Foundayo: with or without food
NeedleYes, a self-injection under the skinNone No needle
Mean weight change, brand trials−20.9% at 72 weeks (Zepbound 15 mg, SURMOUNT-1)−13.6% at 64 weeks (Wegovy tablets 25 mg, OASIS 4)
FDA statusWegovy and Zepbound are approved. Compounded semaglutide and tirzepatide are not FDA approvedAll five are FDA approved FDA approved
Through HarborFrom $89 /mo (compounded, not FDA approved), with medication, clinician care & check-ins in one price Care includedNot offered

Scroll the table sideways to see both columns →

Who should choose a GLP-1 pill or GLP-1 shots

Whether you searched for a GLP 1 pill or for GLP 1 shots, the decision turns on the same three things: how you feel about a needle, which habit fits your week, and what a clinician finds in your history.

Weekly injections may fit better when:

  • You want one dose a week instead of one every day
  • You would rather not plan each morning around a fasting window
  • You want clinician support and aftercare, not just a prescription
  • You are ready for a simple, once-weekly routine at home

A GLP-1 pill may fit better when:

  • You would rather not use a needle
  • A daily tablet fits your routine
  • Your insurance covers an FDA-approved tablet and your own prescriber manages it

Either way, a prescriber looks at your history first. In an August 20, 2026 Trustpilot review, member Leah Nadel wrote that she was "happy that a medical provider is available to answer any questions about my medical health that might interfere with the medication."

The Wegovy, Zepbound and Foundayo labels all rule out people with a personal or family history of medullary thyroid carcinoma or MEN 2, whether the drug is a tablet or an injection. Put your full history and every medicine you take on your intake, and message your clinician with any question about it.

Bottom line on weekly injections with Harbor

Pills and injections can each be the right tool. The weekly route is the one built into a full program here: Harbor compounded semaglutide for gradual, consistent progress, and Harbor compounded tirzepatide for patients whose clinician recommends a two-pathway approach. Both are compounded and not FDA approved.

Semaglutide shots and tirzepatide shots arrive as a prescribed vial with U-100 insulin syringes, alcohol prep pads and a sharps container, according to the program FAQ, and licensed clinicians are available 24/7 for medical questions through the patient portal. When you reach your goal, the plan is a clinician-guided taper and registered-dietitian aftercare. It is a program designed to end.

The online quiz takes about 90 seconds and is the first step toward a physician review. If a weekly injection is not the right fit, it is not prescribed.

This article is for general education and is not medical advice. It is not a substitute for evaluation, diagnosis, or treatment by a licensed clinician. Talk with a qualified clinician about your individual situation.

Harbor is a technology platform. Medical evaluations are conducted by independent, licensed healthcare providers who determine whether treatment is appropriate. Compounded medications are not FDA approved and are not reviewed by the FDA for safety or effectiveness.

Frequently asked questions

It depends on which pill and which injection, and no label trial compares them directly. On the GLP-1 pill vs injection question, current labels report a mean weight change of −13.6% at 64 weeks for Wegovy tablets 25 mg and −14.9% at 68 weeks for Wegovy injection 2.4 mg. Foundayo 17.2 mg reached −11.1% and Zepbound 15 mg reached −20.9%, both at 72 weeks. Those are separate brand-drug trials, and compounded semaglutide and tirzepatide, which are not FDA approved, were not tested in them.

Yes, two. Wegovy tablets (semaglutide) are taken once daily on an empty stomach, and Foundayo (orforglipron) is taken once daily with or without food. Both are FDA approved to reduce excess body weight in adults with obesity, or in adults with overweight and at least one weight-related condition. Rybelsus and Ozempic tablets are also oral semaglutide, but that label covers type 2 diabetes.

No. Harbor's two weight-loss programs, compounded semaglutide and compounded tirzepatide, are once-weekly injections you give yourself at home, and neither is FDA approved. No tablet is offered in any program, brand or compounded. A licensed clinician reviews your intake and decides whether a weekly injection program is appropriate for you.

Sources

  1. Prescription Medications to Treat Overweight & Obesity. National Institute of Diabetes and Digestive and Kidney Diseases, last reviewed June 2024.
  2. WEGOVY (semaglutide) injection and tablets, prescribing information, revised June 2026. DailyMed, U.S. National Library of Medicine.
  3. ZEPBOUND (tirzepatide) injection, prescribing information, revised August 2026. DailyMed, U.S. National Library of Medicine.
  4. FOUNDAYO (orforglipron) tablets, prescribing information. DailyMed, U.S. National Library of Medicine.
  5. RYBELSUS and OZEMPIC (semaglutide) tablets, prescribing information, revised January 2026. DailyMed, U.S. National Library of Medicine.
  6. Compounding and the FDA: questions and answers. U.S. Food and Drug Administration, content current as of September 16, 2025.
  7. STEP 1 (NCT03548935), OASIS 4 (NCT05564117), ATTAIN-1 (NCT05869903) and SURMOUNT-1 (NCT04184622) study records. ClinicalTrials.gov, U.S. National Library of Medicine.
  • GLP-1 Medications

    Six options when weekly Wegovy is out of reach: compounded semaglutide and tirzepatide, which are not FDA approved, plus Zepbound, the Wegovy pill, Foundayo and Saxenda. What each one is and how a clinician chooses.

    By Harbor Health Team

  • GLP-1 Medications

    Appetite suppressants run from short-term prescription pills to fiber, protein and caffeine. Here are seven, each read from its FDA label or NIH evidence, and how GLP‑1 shots prescribed by a clinician compare.

    By Harbor Health Team

  • GLP-1 Medications

    Seven brand GLP 1 shots described from their FDA labels, plus compounded semaglutide and tirzepatide, which are not FDA approved. What each treats, how often you inject it and how to choose.

    By Harbor Health Team